Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2014

Open Access 01-12-2014 | Research

Mefloquine safety and tolerability in pregnancy: a systematic literature review

Authors: Raquel González, Urban Hellgren, Brian Greenwood, Clara Menéndez

Published in: Malaria Journal | Issue 1/2014

Login to get access

Abstract

Background

Control of malaria in pregnant women is still a major challenge as it constitutes an important cause of maternal and neonatal mortality. Mefloquine (MQ) has been used for malaria chemoprophylaxis in non-immune travellers for several decades and it constitutes a potential candidate for intermittent preventive treatment in pregnant women (IPTp).

Methods

The safety of MQ, including its safety in pregnancy, is controversial and a continuing subject of debate. Published studies which evaluated the use of MQ for malaria prevention or treatment in pregnant women and which reported data on drug tolerability and/or pregnancy outcomes have been reviewed systematically.

Results

Eighteen articles fitted the inclusion criteria, only one study was double-blind and placebo controlled. No differences were found in the risk of adverse pregnancy outcomes in women exposed to MQ compared to those exposed to other anti-malarials or to the general population. MQ combined with artesunate seems to be better tolerated than standard quinine therapy for treatment of non-severe falciparum malaria, but a MQ loading dose (10 mg/kg) is associated with more dizziness compared with placebo. When used for IPTp, MQ (15 mg/kg) may have more side effects than sulphadoxine- pyrimethamine.

Conclusions

In the published literature there are no indications that MQ use during pregnancy carries an increased risk for the foetus. Ideally, the use of MQ to prevent malaria should be based on a risk-benefit analysis of adverse effects against the risk of acquiring the infection. For this purpose double-blinded randomized controlled trials in African pregnant women are much needed.
Appendix
Available only for authorised users
Literature
1.
Granja ACMF, Bergstrom S: Avoidability of maternal death in Mozambique: audit and retrospective risk assessment in 106 consecutive cases. Afr J Health Sci. 2000, 7: 83-87.PubMed
2.
Menendez C, Bardaji A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E, Macete E, Berenguera A, David C, Dobano C, Naniche D, Mayor A, Ordi J, Mandomando I, Aponte JJ, Mabunda S, Alonso PL: A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS One. 2008, 3: e1934-10.1371/journal.pone.0001934.PubMedCentralCrossRefPubMed
3.
4.
Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD: Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007, 7: 93-104. 10.1016/S1473-3099(07)70021-X.CrossRefPubMed
5.
Greenwood BM GA, Snow RW, Byass P, Bennett S, Hatib N`Jie AB: The effects of malaria chemoprophylaxis given by traditional birth attendantes on the course and outcome of pregnancy. Trans R Soc Trop Med Hyg. 1989, 83: 589-594. 10.1016/0035-9203(89)90362-3.CrossRefPubMed
6.
Guyatt HL, Snow RW: Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev. 2004, 17: 760-769. 10.1128/CMR.17.4.760-769.2004. table of contentsPubMedCentralCrossRefPubMed
7.
Le Hesran JY, Fievet N, Thioulouse J, Personne P, Maubert B, M'Bidias S, Etye'ale D, Cot M, Deloron P: Development of cellular immune responses to Plasmodium falciparum blood stage antigens from birth to 36 months of age in Cameroon. Acta Trop. 2006, 98: 261-269. 10.1016/j.actatropica.2006.05.010.CrossRefPubMed
8.
Menendez C, D'Alessandro U, ter Kuile FO: Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis. 2007, 7: 126-135. 10.1016/S1473-3099(07)70024-5.CrossRefPubMed
9.
Menendez C, Mayor A: Congenital malaria: the least known consequence of malaria in pregnancy. Semin Fetal Neonatal Med. 2007, 12: 207-213. 10.1016/j.siny.2007.01.018.CrossRefPubMed
10.
Menendez C, Ordi J, Ismail MR, Ventura PJ, Aponte JJ, Kahigwa E, Font F, Alonso PL: The impact of placental malaria on gestational age and birth weight. J Infect Dis. 2000, 181: 1740-1745. 10.1086/315449.CrossRefPubMed
11.
Schwarz NG, Adegnika AA, Breitling LP, Gabor J, Agnandji ST, Newman RD, Lell B, Issifou S, Yazdanbakhsh M, Luty AJ, Kremsner PG, Grobusch MP: Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis. 2008, 47: 1017-1025. 10.1086/591968.CrossRefPubMed
12.
DE Shulman CE, Bulmer JN: Malaria as a cause of severe anaemia in pregnancy. Lancet. 2002, 360: 494-CrossRef
13.
Steketee RW, Nahlen BL, Parise ME, Menendez C: The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001, 64: 28-35.PubMed
14.
Steketee RW, Wirima JJ, Hightower AW, Slutsker L, Heymann DL, Breman JG: The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg. 1996, 55: 33-41.PubMed
15.
van Geertruyden JP, Thomas F, Erhart A, D'Alessandro U: The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg. 2004, 71: 35-40.PubMed
16.
WHO: A strategic framework for malaria prevention and control during pregnancy in the African region. 2004, Geneva: World Health Organization, AFR/MAL/04/01
17.
18.
Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, Vanden Eng J, Owino SO, Lal AA, Omosun YO, Otieno K, Desai M, Ter Kuile FO, Nahlen B, Moore J, Hamel MJ, Ouma P, Slutsker L, Shi YP: Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar J. 2012, 11: 134-10.1186/1475-2875-11-134.PubMedCentralCrossRefPubMed
19.
Menendez C, Serra-Casas E, Scahill MD, Sanz S, Nhabomba A, Bardaji A, Sigauque B, Cistero P, Mandomando I, Dobano C, Alonso PL, Mayor A: HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment. Clin Infect Dis. 2011, 52: 41-48. 10.1093/cid/ciq049.CrossRefPubMed
20.
Mockenhaupt FP, Bedu-Addo G, Eggelte TA, Hommerich L, Holmberg V, von Oertzen C, Bienzle U: Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. J Infect Dis. 2008, 198: 1545-1549. 10.1086/592455.CrossRefPubMed
21.
Taylor SM, Antonia A, Feng G, Mwapasa V, Chaluluka E, Molyneux M, ter Kuile FO, Rogerson SJ, Meshnick SR: Adaptive evolution and fixation of drug-resistant Plasmodium falciparum genotypes in pregnancy-associated malaria: 9-year results from the QuEERPAM study. Infect Genet Evol. 2012, 12: 282-290. 10.1016/j.meegid.2011.11.006.PubMedCentralCrossRefPubMed
22.
Briand V, Bottero J, Noel H, Masse V, Cordel H, Guerra J, Kossou H, Fayomi B, Ayemonna P, Fievet N, Massougbodji A, Cot M: Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis. 2009, 200: 991-1001. 10.1086/605474.CrossRefPubMed
23.
Na Bangchang K, Davis TM, Looareesuwan S, White NJ, Bunnag D, Karbwang J: Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg. 1994, 88: 321-323. 10.1016/0035-9203(94)90101-5.CrossRefPubMed
24.
Nosten F, Karbwang J, White NJ, Honeymoon N, Bangchang K, Bunnag D, Harinasuta T: Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol. 1990, 30: 79-85. 10.1111/j.1365-2125.1990.tb03746.x.PubMedCentralCrossRefPubMed
25.
Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R: Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007, 7: 136-144. 10.1016/S1473-3099(07)70025-7.CrossRefPubMed
26.
Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG: The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J. 2010, 9: 357-10.1186/1475-2875-9-357.PubMedCentralCrossRefPubMed
27.
28.
29.
Sevene E, Gonzalez R, Menendez C: Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. Expert Opin Pharmacother. 2010, 11: 1277-1293. 10.1517/14656561003733599.CrossRefPubMed
30.
Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, Phillips-Howard P, Nevill C, Sturchler D: Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet. 1993, 341: 1299-1303. 10.1016/0140-6736(93)90814-W.CrossRefPubMed
31.
van Riemsdijk MM, Sturkenboom MC, Ditters JM, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH: Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol. 2004, 57: 506-512. 10.1046/j.1365-2125.2003.02035.x.PubMedCentralCrossRefPubMed
32.
ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ: High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis. 1992, 166: 1393-1400. 10.1093/infdis/166.6.1393.CrossRefPubMed
33.
34.
Nevin RL: Limitations of postmarketing surveillance in the analysis of risk of pregnancy loss associated with maternal mefloquine exposure. Clin Infect Dis. 2012, 55: 1167-1168. 10.1093/cid/cis601. author reply 1168-1169CrossRefPubMed
35.
36.
Collignon P, Hehir J, Mitchell D: Successful treatment of falciparum malaria in pregnancy with mefloquine. Lancet. 1989, 1: 967-CrossRefPubMed
37.
Sweeney TR: The present status of malaria chemotherapy: mefloquine, a novel antimalarial. Med Res Rev. 1981, 1: 281-301. 10.1002/med.2610010304.CrossRefPubMed
38.
Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F: Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009, 4: e4551-10.1371/journal.pone.0004551.PubMedCentralCrossRefPubMed
39.
Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ: Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000, 356: 297-302. 10.1016/S0140-6736(00)02505-8.CrossRefPubMed
40.
McGready R, Brockman A, Cho T, Cho D, van Vugt M, Luxemburger C, Chongsuphajaisiddhi T, White NJ, Nosten F: Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 2000, 94: 689-693. 10.1016/S0035-9203(00)90235-9.CrossRefPubMed
41.
Orton LC, Omari AA: Drugs for treating uncomplicated malaria in pregnant women. Cochr Database Syst Rev (Online). 2008, 4: CD004912-
42.
43.
McGready R, Cho T, Hkirijaroen L, Simpson J, Chongsuphajaisiddhi T, White NJ, Nosten F: Quinine and mefloquine in the treatment of multidrug-resistan Plasmodium falciparum malaria in pregnancy. Ann Trop Med Parasit. 1998, 92: 643-653. 10.1080/00034989859104.CrossRefPubMed
44.
Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ: The effects of mefloquine treatment in pregnancy. Clin Infect Dis. 1999, 28: 808-815. 10.1086/515183.CrossRefPubMed
45.
Harinasuta T, Kietinun S, Somlaw S, Bunnag D, Sheth U, Wernsdorfer W: A clinical trial of mefloquine on multi-resistant falciparum malaria in pregnant women in Thailand. Bull Soc Fr Parasitol. 1990, 429-
46.
Adam I, Ali DA, Alwaseila A, Kheir MM, Elbashir MI: Mefloquine in the treatment of falciparum malaria during pregnancy in Eastern Sudan. Saudi Med J. 2004, 25: 1400-1402.PubMed
47.
Okeyeh JN, Lege-Oguntoye L, Emembolu JO, Agbo M: Malaria in pregnancy: efficacy of a low dose of mefloquine in an area holoendemic for multi-drug resistant Plasmodium falciparum. Ann Trop Med Parasit. 1996, 90: 265-268.PubMed
48.
Bounyasong S: Randomized trial of artesunate and mefloquine in comparison with quinine sulfate to treat P. falciparum malaria pregnant women. J Med Assoc Thai. 2001, 84: 1289-1299.PubMed
49.
Sowunmi A, Oduola AM, Ogundahunsi OA, Fehintola FA, Ilesanmi OA, Akinyinka OO, Arowojolu AO: Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sufadoxine-pyrimethamine-resistant falciparum malaria during pregnancy. J Obstet Gynaecol. 1998, 18: 322-327. 10.1080/01443619867038.CrossRefPubMed
50.
Nosten F, ter Kuile F, Maelankiri L, Chongsuphajaisiddhi T, Nopdonrattakoon L, Tangkitchot S, Boudreau E, Bunnag D, White NJ: Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis. 1994, 169: 595-603. 10.1093/infdis/169.3.595.CrossRefPubMed
51.
Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG: Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg. 1996, 55: 50-56.PubMed
52.
Steketee RW, Wirima JJ, Slutsker L, Roberts JM, Khoromana CO, Heymann DL, Breman JG: Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg. 1996, 55: 24-32.PubMed
53.
Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL: The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. J Infect Dis. 1997, 176: 831-833. 10.1086/517315.CrossRefPubMed
54.
Vanhauwere B, Maradit H, Kerr L: Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg. 1998, 58: 17-21.PubMed
55.
Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E, Edwards R: Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med. 1998, 5: 121-126. 10.1111/j.1708-8305.1998.tb00484.x.CrossRefPubMed
56.
Denoeud-Ndam L, Clement MC, Briand V, Akakpo J, Agossou VK, Atadokpede F, Dossou-Gbete L, Komongui DG, Afangnihoun A, Girard PM, Zannou DM, Cot M: Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in Benin. J Acquir Immune Defic Syndrom. 2012, 61: 64-72. 10.1097/QAI.0b013e3182615a58.CrossRef
57.
Schlagenhauf P, Blumentals WA, Suter P, Regep L, Vital-Durand G, Schaerer MT, Boutros MS, Rhein HG, Adamcova M: Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis. 2012, 54: e124-e131. 10.1093/cid/cis215.PubMedCentralCrossRefPubMed
58.
Nevin RL: Mefloquine gap junction blockade and risk of pregnancy loss. Biol Reprod. 2012, 87: 65-10.1095/biolreprod.112.099614.CrossRefPubMed
59.
Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D: Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Int Med. 2004, 141: 781-788. 10.7326/0003-4819-141-10-200411160-00009.CrossRefPubMed
60.
Lutfullin A, Kuhlmann J, Wensing G: Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1,559 subjects. Int J Clin Pharmacol Ther. 2005, 43: 217-226. 10.5414/CPP43217.CrossRefPubMed
61.
Sibille M, Deigat N, Janin A, Kirkesseli S, Durand DV: Adverse events in phase-I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol. 1998, 54: 13-20. 10.1007/s002280050413.CrossRefPubMed
62.
Bardaji A, Sigauque B, Bruni L, Romagosa C, Sanz S, Mabunda S, Mandomando I, Aponte J, Sevene E, Alonso PL, Menendez C: Clinical malaria in African pregnant women. Malar J. 2008, 7: 27-10.1186/1475-2875-7-27.PubMedCentralCrossRefPubMed
63.
Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW: Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health. 2003, 8: 488-506. 10.1046/j.1365-3156.2003.01066.x.CrossRefPubMed
64.
Nosten FMR, d’Alessandro U, Bonell A, Verhoeff F, Menendez C, Mutabingwa T, Brabin B: Antimalarial Drugs in Pregnancy: A Review. Curr Drug Saf. 2006, 1: 1-15. 10.2174/157488606775252584.CrossRefPubMed
65.
66.
Denoeud-Ndam L, Zannou DM, Fourcade C, Taron-Brocard C, Porcher R, Atadokpede F, Komongui DG, Dossou-Gbete L, Afangnihoun A, Ndam NT, Girard PM, Cot M: Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials. J Acquir Immune Defic Syndrom. 2014, 65: 198-206. 10.1097/QAI.0000000000000058.CrossRef
67.
Gonzalez R, Ataide R, Naniche D, Menendez C, Mayor A: HIV and malaria interactions: where do we stand?. Expert Rev Anti Infect Ther. 2012, 10: 153-165. 10.1586/eri.11.167.CrossRefPubMed
Metadata
Title
Mefloquine safety and tolerability in pregnancy: a systematic literature review
Authors
Raquel González
Urban Hellgren
Brian Greenwood
Clara Menéndez
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2014
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-13-75

Other articles of this Issue 1/2014

Malaria Journal 1/2014 Go to the issue

Research

In vitro and in vivo combination of cepharanthine with anti-malarial drugs

Review

A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission

Research

Stability profiling of anti-malarial drug piperaquine phosphate and impurities by HPLC-UV, TOF-MS, ESI-MS and NMR

Research

Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial

Research

Estimation of insecticide persistence, biological activity and mosquito resistance to PermaNet® 2 long-lasting insecticidal nets over three to 32 months of use in Ethiopia

Research

Distribution and utilization of vector control strategies in a malarious village of Jabi Tehnan District, north-western Ethiopia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits